A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk (HEART-C)
A Single-arm Evaluation of the Effect of Elbasvir/Grazoprevir on Cardiometabolic Parameters in Patients With Hepatitis C Infection and Underlying Metabolic Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90025
- UCLA CARE Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women ≥ 18 years of age.
- Presence of HCV infection for at least 12 weeks
- Serum or plasma HCV RNA > lower limit of quantification or detection at any time before or at the time of screening, and the absence of intervening HCV treatment
- Absence of HIV infection
- HCV treatment-naïve OR HCV treatment-experienced with PEG-IFN/RBV only (no prior HCV DAA exposure)
- Genotype 1 or 4 HCV infection. If HCV genotype 1a infection is present, absence of genotype 1a NS5A resistance associated substitutions (RASs) at amino acid positions 28, 30, 31, and 93 must be documented at screening
Evidence of metabolic disease defined as:
Insulin resistance or impaired glucose tolerance by one of the following:
- HOMA-IR ≥2.5 at screening
- Hemoglobin A1c 5.7-6.4% at screening
- Diabetes mellitus with hemoglobin A1c <7% at screening and never on more than one oral hypoglycemic agent, as well as never requiring insulin
OR
Metabolic Syndrome, defined as at least 3 of the following:
- Waist circumference ≥102 cm for men and ≥ 88 cm for women
- Serum triglyceride level ≥150 mg/dL or on a triglyceride lowering agent
- Serum high-density lipoprotein (HDL) cholesterol <40 mg/dL in men and <50 mg/dL in women or drug treatment for low HDL cholesterol
- Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure
- Fasting blood glucose ≥100 mg/dL
- Ability and willingness of subject to provide written informed consent
Exclusion Criteria:
- History of decompensated liver disease (Child Pugh Class B or C)
- Albumin below 3 g/dL
- Platelet count below 75,000
- HBsAg positivity.
- Pregnancy or breastfeeding
- Inability to conform to the following drug interruptions for PAT testing, whether due to safety (determined by the investigator) or willingness: No caffeine or recreational or prescription stimulant use for 24 hours prior; no nicotine for 4 hours prior; no vigorous exercise for 12 hours prior; stopping of beta blockers, short-acting calcium channel blockers (CCBs), nitrates, angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin-receptor blockers (ARBs), and renin-inhibitors for 24 hours prior; and stopping of long acting CCBs 48 hours prior to testing.
- Use of anticoagulant or antiplatelet agents (other than aspirin ≤ 325 mg orally daily) within 1 week prior to study entry or anticipated need for these agents for >7 days during the study follow-up period.
- Use of contraindicated concomitant medications, including OATP1B1/3 inhibitors and strong CYP3A inducers
- Serious illness including acute liver-related disease and malignancy requiring systemic treatment or hospitalization within 12 weeks prior to study entry.
- History of major organ transplantation with an existing functional graft and on immunosuppressive therapy.
- History of known vascular disorder or autoimmune processes including Crohn's disease, ulcerative colitis, severe psoriasis, rheumatoid arthritis, and cryoglobulinemia that may affect vascular studies.
- Decompensated congestive heart failure or acute cardiovascular event (such as stroke, myocardial infarction, arrhythmia, acute peripheral arterial insufficiency) within 6 months prior to study entry
- Use of immune-based therapies or systemic corticosteroids which may affect vascular studies or inflammatory/endothelial biomarkers within 12 weeks prior to study entry
- Advanced renal insufficiency as defined by glomerular filtration rate (GFR) < 30 mL/min/1.73 m2 or treatment by dialysis
- Anticipated inability to comply with research study visits as determined by the investigator
- Poor venous access not allowing screening laboratory collection
- Having any condition that the investigator considers a contraindication to study participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: All participants
Intervention: Elbasvir/grazoprevir
|
Daily fixed-dose combination (FDC) elbasvir (EBR) (50 mg)/grazoprevir (GZR) (100 mg) for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in reactive hyperemia index (RHI) by peripheral arterial tonometry (PAT)
Time Frame: Baseline to 12 weeks after end of EBR/GZR treatment.
|
Baseline to 12 weeks after end of EBR/GZR treatment.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in insulin resistance by HOMA-IR
Time Frame: Baseline to 12 weeks after end of treatment
|
Baseline to 12 weeks after end of treatment
|
|
Change in reactive hyperemia index (RHI) by PAT
Time Frame: Baseline to week 4 on treatment
|
Baseline to week 4 on treatment
|
|
Change in reactive hyperemia index (RHI) by PAT
Time Frame: Baseline to 52 weeks after end of treatment
|
Baseline to 52 weeks after end of treatment
|
|
Change in insulin resistance by HOMA-IR
Time Frame: Baseline to week 4 on treatment
|
Baseline to week 4 on treatment
|
|
Change in insulin resistance by HOMA-IR
Time Frame: Baseline to 52 weeks after end of treatment
|
Baseline to 52 weeks after end of treatment
|
|
Change in hemoglobin A1c
Time Frame: Baseline to week 4, baseline to 12 weeks after end of treatment, and baseline to 52 weeks after end of treatment
|
Baseline to week 4, baseline to 12 weeks after end of treatment, and baseline to 52 weeks after end of treatment
|
|
Change in total and LDL cholesterol levels
Time Frame: Baseline to week 4, baseline to 12 weeks after end of treatment, and baseline to 52 weeks after end of treatment
|
Baseline to week 4, baseline to 12 weeks after end of treatment, and baseline to 52 weeks after end of treatment
|
|
Change in levels of each soluble biomarker (sCD163, sCD14, sICAM-1, PAI-1, sE-selectin, oxidized LDL, Lp-PLA2, and lipoprotein particle quantification)
Time Frame: Baseline to week 4, baseline to 12 weeks after end of treatment, and baseline to 52 weeks after end of treatment
|
Baseline to week 4, baseline to 12 weeks after end of treatment, and baseline to 52 weeks after end of treatment
|
|
Cross-sectional levels of each soluble biomarker (sCD163, sCD14, sICAM-1, PAI-1, sE-selectin, oxidized LDL, Lp-PLA2, and lipoprotein particle quantification) at each time point for correlation with RHI
Time Frame: Baseline, week 4, post-treatment weeks 12 and 52
|
Baseline, week 4, post-treatment weeks 12 and 52
|
|
Cross-sectional fibrosis score in kPa by transient elastography (TE) for correlation with RHI and soluble biomarkers
Time Frame: Baseline and 12 and 52 weeks after end of treatment
|
Baseline and 12 and 52 weeks after end of treatment
|
|
Cross-sectional steatosis score in dB/m by CAP for correlation with RHI and soluble biomarkers at the same time points
Time Frame: Baseline and 12 and 52 weeks after end of treatment
|
Baseline and 12 and 52 weeks after end of treatment
|
|
Change in fibrosis score by transient elastography
Time Frame: Baseline to 52 weeks after end of treatment
|
Baseline to 52 weeks after end of treatment
|
|
Change in hepatic steatosis score by CAP
Time Frame: Baseline to 52 weeks after end of treatment
|
Baseline to 52 weeks after end of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Kara W Chew, M.D., M.S., University of California, Los Angeles
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Cardiovascular Diseases
- Hepatitis
- Hepatitis A
- Hepatitis C
- Metabolic Diseases
- Anti-Infective Agents
- Antiviral Agents
- Grazoprevir
- Elbasvir-grazoprevir drug combination
Other Study ID Numbers
Other Study ID Numbers
- 18-000650
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.